Sanders Kelly E, Hatton Gabrielle E, Mankame Atharwa R, Allen Addison C, Cunningham Sarah, Van Gent Jan Michael, Fox Erin E, Zhang Xu, Wade Charles E, Cotton Bryan A, Cardenas Jessica C
From the Center for Translational Injury Research, Department of Surgery (K.E.S., G.E.H., A.R.M., A.C.A., S.C., J.M.V.G., E.E.F., C.E.W., B.A.C., J.C.C.), McGovern Medical School, and Center for Clinical and Translational Sciences (X.Z.), The University of Texas Health Science Center, Houston, Texas.
J Trauma Acute Care Surg. 2024 Nov 1;97(5):690-696. doi: 10.1097/TA.0000000000004319. Epub 2024 Mar 25.
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in trauma patients, despite chemoprophylaxis. Statins have been shown capable of acting upon the endothelium. We hypothesized that statin therapy in the pre- or in-hospital settings leads to a decreased incidence of VTE.
We conducted a retrospective cohort study of injured patients who received statin therapy pre- or in-hospital. Adult, highest-level trauma activation patients admitted from January 2018 to June 2022 were included. Patients on prehospital anticoagulants, had history of inherited bleeding disorder, and who died within the first 24 hours were excluded. Statin users were matched to nonusers by statin use indications including age, current heart and cardiovascular conditions and history, hyperlipidemia, injury severity, and body mass index. Time to in-hospital statin initiation and occurrence of VTE and other complications within 60 days were collected. Differences between groups were determined by univariate, multivariable logistic regression, and Cox proportional hazard analyses.
Of 3,062 eligible patients, 79 were statin users, who were matched to 79 nonusers. There were no differences in admission demographics, vital signs, injury pattern, transfusion volumes, lengths of stay, or mortality between groups. The overall VTE incidence was 10.8% (17 of 158). Incidence of VTE in statin users was significantly lower (3%) than nonusers (19%; p = 0.003). Differences between statin users and nonusers were observed for rates of deep vein thrombosis (0% vs. 9%), pulmonary embolism (3% vs. 15%), and sepsis (0% vs. 5%). Exposure to statins was associated with an 82% decreased risk of developing VTE (hazard ratio, 0.18; 95% confidence interval, 0.04-0.86; p = 0.033).
Statin exposure was associated with decline in VTE and lower individual rates of deep vein thrombosis, pulmonary embolism, and sepsis. Our findings indicate that statins should be evaluated further as a possible adjunctive therapy for VTE chemoprophylaxis after traumatic injury.
Therapeutic/Care Management; Level IV.
尽管采取了化学预防措施,但静脉血栓栓塞症(VTE)仍是创伤患者发病和死亡的主要原因。他汀类药物已被证明能够作用于血管内皮。我们推测,在院前或院内使用他汀类药物治疗可降低VTE的发生率。
我们对院前或院内接受他汀类药物治疗的受伤患者进行了一项回顾性队列研究。纳入2018年1月至2022年6月收治的成年、最高级创伤激活患者。排除院前使用抗凝剂、有遗传性出血性疾病史以及在最初24小时内死亡的患者。根据他汀类药物使用指征,将他汀类药物使用者与非使用者进行匹配,包括年龄、当前心脏和心血管疾病及病史、高脂血症、损伤严重程度和体重指数。收集院内开始使用他汀类药物的时间以及60天内VTE和其他并发症的发生情况。通过单变量、多变量逻辑回归和Cox比例风险分析确定组间差异。
在3062例符合条件的患者中,79例为他汀类药物使用者,与79例非使用者进行匹配。两组在入院人口统计学、生命体征、损伤模式、输血量、住院时间或死亡率方面无差异。总体VTE发生率为10.8%(158例中的17例)。他汀类药物使用者的VTE发生率显著低于非使用者(3%对19%;p = 0.003)。在深静脉血栓形成率(0%对9%)、肺栓塞率(3%对15%)和脓毒症率(0%对5%)方面,观察到他汀类药物使用者与非使用者之间存在差异。使用他汀类药物与发生VTE的风险降低82%相关(风险比,0.18;95%置信区间,0.04 - 0.86;p = 0.033)。
使用他汀类药物与VTE发生率下降以及深静脉血栓形成、肺栓塞和脓毒症的个体发生率降低相关。我们的研究结果表明,他汀类药物应作为创伤后VTE化学预防的一种可能辅助治疗方法进行进一步评估。
治疗/护理管理;四级。